References
- 1. Pelosof MD, PHD LC, Gerber MD DE. Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment. Mayo Clin Proc. 2010;
- 2. Zeineddine N, Khoury L El, Mosak J. Systemic Sclerosis and Malignancy: A Review of Current Data. J Clin Med Res. 2016;
- 3. Krämer A. Metastases in the Absence of a Primary Tumor – Advances in the Diagnosis and Treatment of CUP Syndrome: In reply. Dtsch Aerzteblatt Online. 2009;
- 4. Szekanecz Z, Szekanecz É, Bakó G, Shoenfeld Y. Malignancies in autoimmune rheumatic diseases - A mini-review. Gerontology. 2010.
- 5. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: A systematic review and meta-analysis of cohort studies. Rheumatol (United Kingdom). 2012;
- 6. Racanelli V, Prete M, Minoia C, Favoino E, Perosa F. Rheumatic disorders as paraneoplastic syndromes. Autoimmunity Reviews. 2008.1848692110.1016/j.autrev.2008.02.001
- 7. Ciołkiewicz M, Domysławska I, Ciołkiewicz A, Klimiuk PA, Kuryliszyn-Moskal A. Coexistence of systemic sclerosis, scleroderma-like syndromes and neoplastic diseases. Polskie Archiwum Medycyny Wewnetrznej. 2008.
- 8. Madrid FF, Maroun MC. Serologic laboratory findings in malignancy. Rheumatic Disease Clinics of North America. 2011.
- 9. Zuber M. Positive antinuclear antibodies in malignancies [3]. Annals of the Rheumatic Diseases. 1992.10.1136/ard.51.4.573-b
- 10. Solans-Laqué R, Pérez-Bocanegra C, Salud-Salvia A, Fonollosa-Plá V, Rodrigo MJ, et al. Clinical significance of antinuclear antibodies in malignant diseases: Association with rheumatic and connective tissue paraneoplastic syndromes. Lupus. 2004;
- 11. Wen J, Ouyang H, Yang R, Bo L, Zhang Y, Tang M, et al. Malignancy dominated with rheumatic manifestations: A retrospective single-center analysis. Sci Rep. 2018;